Banner - Collaborative Care Symposium
News
All NewsContributorsMoney Matters
Media
All VideosExpert InterviewsMedical World NewsPodcastsBeyond The WallsCase Based Roundtable SeriesCase of the QuarterEyeViewGrand RoundsInsightsRapid ReadoutSpecial ReportViewpointsWhat’s Your WhEYE?
Conferences
Conference CoverageConference Listing
Events
More
Publications
Digital EditionEurope Ophthalmology TimesModern RetinaSupplements and Featured Publications
CME
Partners
Resources
Job BoardSponsored

Subscribe

  • News
  • Media
  • Conferences
  • Events
  • Publications
  • CME
  • Partners
  • Subscribe
  • Resources
  • AMD
  • Biosimilars
  • COVID-19
  • Cataract
    • Cataract Surgery
  • Cataract Therapeutics
  • Clinical Diagnosis
    • The Residency Report
    • iOpeners
    • NeuroOp Guru
  • Cornea
  • DME
  • Dry Eye
    • Dry Eye Awareness
  • Gene Therapy
  • Geographic Atrophy
  • IOL
    • IOL Advances
  • Imaging
  • Interventional Glaucoma
    • Glaucoma Awareness
    • Glaucoma Insights
    • Therapeutic Glaucoma
  • OCT
  • Ocular Allergy
  • Ocular Surface Disease
  • Optic Relief
  • Optometry
  • Pediatrics
  • Pharmacy
  • Practice Management
    • Indispensable
  • Presbyopia
  • Ptosis
  • Refractive
    • Refractive Surgery
  • Retina
  • Surgery
  • Technology
  • Therapeutics
  • Understanding Antibiotic Resistance
  • Workplace
Spotlight -
Retina
Advertisement

Lisa Stewart, PhD

Advertisement

Articles by Lisa Stewart, PhD

Dietary supplement can improve measurable visual outcomes

ByLisa Stewart, PhD
January 19th 2021

Higher levels of 3 macular pigments minimize risk of age-related disease.

Advertisement

Latest Updated Articles



    Advertisement
    Advertisement

    Trending on Ophthalmology Times - Clinical Insights for Eye Specialists

    1

    FDA approves Amneal Pharmaceuticals' cyclosporine ophthalmic emulsion 0.05%

    2

    Inflammasome Therapeutics completes phase 2 trial enrollment for K8 in GA

    3

    Eydenzelt, Celltrion’s biosimilar referencing Eylea, approved in Canada

    4

    Lotus submits NDA in South Korea for LENZ’s presbyopia treatment VIZZ

    5

    Belite Bio releases topline results from phase 3 DRAGON trial of Tinlarebant for STGD1

    • About
    • Advertise
    • Privacy
    • Editorial Info
    • Editorial Board
    • Terms and Conditions
    • Contact Us
    • Do Not Sell My Personal Information
    • Job Board
    Contact Info

    259 Prospect Plains Rd, Bldg H
    Cranbury, NJ 08512

    609-716-7777

    • Ophthalmology Times
    • Modern Retina
    • Optometry Times
    • Ophthalmology Times Europe
    EyeCare Network
    Brand Logo

    © 2025 MJH Life Sciences®

    All rights reserved.

    Home
    About Us
    News
    Contact Us